You have an old version of Adobe's Flash Player. Get the latest Flash player.
HomeAbout UsGalleryNewsOrganizational UnitsProductsChartContact Us

Mefenamic acid






Each capsule contains:  Mefenamic acid     250 mg



Treatment of Mild to Moderate Pain, Primary Dysmenorrhea


Dosage and administration:


Take the medicine with or just after food, or a meal.



Mild to Moderate Pain (≥14 Years):

Usual: 500mg as initial dose, followed by 250mg q6h prn for ≤1 week.

Primary Dysmenorrhea

Usual: 500mg as initial dose, followed by 250mg q6h for 2-3 days.

Start with the onset of bleeding and associated symptoms .




Pregnancy & Breastfeeding:

Category C, not for nursing.



Preexisting renal disease, acute active ulceration or chronic inflammation of the upper/lower GI tract.

History of asthma, urticaria, or allergic-type reactions after taking aspirin (ASA) or other NSAIDs.

Treatment of perioperative pain in the setting of CABG surgery.


Precaution & warnings:

Use lowest effective dose for shortest duration possible to minimize risk for CV events and adverse GI events.

May lead to onset of new HTN or worsening of preexisting HTN; caution with HTN and monitor BP closely at initiation and throughout the course of therapy.

Fluid retention and edema reported; caution with fluid retention or heart failure (HF).

Caution with prior history of ulcer disease or GI bleeding.

Increased risk of GI bleeding with longer duration of NSAID therapy, older age, and poor general health status; monitor for GI ulceration/bleeding and d/c therapy until a serious GI adverse event is ruled out.

 Consider alternate therapies that do not involve NSAIDs in high risk patients.

Renal papillary necrosis, and other renal injury reported after long-term use. Increased risk of renal toxicity with impaired renal function, HF, and liver dysfunction.

Not recommended for use with advanced renal disease.

 Anaphylactoid reactions may occur; avoid in patients with ASA triad.

May cause serious skin adverse events (eg, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at 1st appearance of skin rash/hypersensitivity.

 Avoid in late pregnancy; may cause premature closure of ductus arteriosus.

 Not a substitute for corticosteroids nor treatment for corticosteroid insufficiency; abrupt discontinuation of corticosteroids may lead to disease exacerbation.

 Elevations of LFTs and severe hepatic reactions (eg, jaundice, fatal fulminant hepatitis, liver necrosis, hepatic failure) reported; discontinue if liver/renal disease or systemic manifestations occur and if abnormal LFTs persist/worsen.

 Anemia reported; with long-term use, monitor Hgb/Hct if signs/symptoms of anemia develop.

May inhibit platelet aggregation and prolong bleeding time; monitor patients with coagulation disorders.

Caution with asthma and avoid with ASA-sensitive asthma.

Caution in debilitated patients and elderly.


Side effects:

Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, GI ulcers, nausea, vomiting, anemia, dizziness, edema, headache, rashes.


Drug interaction:

Increased risk of GI bleeding with oral corticosteroids, anti-coagulants, alcohol use, and smoking.

May have impaired response to thiazides or loop diuretics.

May diminish antihypertensive effects of ACE-inhibitors.

ASA may increase adverse effects; concomitant use not recommended.

May reduce natriuretic effect of furosemide and thiazides; monitor for renal failure and diuretic efficacy.

May increase lithium levels; monitor for lithium toxicity.

Enhances methotrexate toxicity; caution with concomitant use.

Antacids containing magnesium hydroxide may increase mefenamic acid levels.

May prolong PT with oral anticoagulants; monitor PT frequently.



Store below 30°C.

Keep out of reach of children.

All rights reserved by Razak Laboratory Co.